Eli Lilly and Novo Nordisk report GLP-1 drugs may slow biological aging

Eli Lilly and Novo Nordisk have reported findings suggesting their blockbuster GLP-1 weight-loss drugs may slow biological aging by reducing molecular markers of age. The studies, presented at the Aging Research & Drug Discovery conference, used aging clocks to measure effects in overweight or diabetic patients. While the results are unverified, they could reshape the future of longevity therapeutics.

What the research shows

According to MIT Technology Review, drugmakers Eli Lilly and Novo Nordisk have presented findings suggesting their GLP-1 weight-loss drugs—semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound)—may slow biological aging in overweight or diabetic patients. The studies used molecular 'aging clocks,' tools that measure biological age through proteomic and epigenetic markers, to compare patients taking the drugs to those on a placebo.

The reported reduction in biological age ranges from 2 to 3 years, with some clocks indicating up to 4 years of reversal. These findings imply that GLP-1 drugs could function as geroprotectors, targeting underlying mechanisms of aging rather than just managing weight or diabetes.

Beyond aging, these drugs have been associated with broader health improvements, including better kidney function, lower blood pressure, and a reduced risk of mortality.

Next steps and commercial implications

To validate these findings, the U.S. agency ARPA-H has allocated $38 million for a study investigating semaglutide’s anti-aging effects in healthy individuals over 60. The study aims to define a regulatory pathway for anti-aging drugs and foster a new therapeutic industry around longevity.

The commercial potential of GLP-1 drugs is already significant. Eli Lilly’s tirzepatide generated over $36 billion in revenue last year, making it the world’s best-selling drug. If anti-aging claims are substantiated, the market for these therapies could expand further, attracting investment in longevity-focused startups and technologies.

However, the drugs are not without side effects, including muscle loss, which may limit their appeal for long-term use in otherwise healthy individuals.

The science behind aging clocks

Aging clocks are computational models that estimate biological age by analyzing molecular markers, such as proteins or epigenetic modifications. Unlike chronological age, biological age reflects the physiological state of tissues and organs, offering insights into how quickly—or slowly—a person is aging.

Proteomic clocks focus on patterns in protein levels, while epigenetic clocks examine chemical modifications to DNA, such as DNA methylation. These tools are increasingly used in drug development to assess whether therapies can delay or reverse age-related changes.

Developing: what is not yet confirmed

The following is reported but has not been independently confirmed.

The findings reported by MIT Technology Review remain unverified, as the underlying data has not been independently confirmed or peer-reviewed. While the use of aging clocks is a promising approach, the results should be interpreted with caution until further validation is completed.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

For founders and operators in biotech and longevity, this research signals a pivotal shift in how GLP-1 drugs are positioned—beyond weight loss and diabetes management. If these drugs genuinely slow biological aging, they could redefine preventive medicine, creating opportunities for new business models in personalized healthcare, diagnostics, and even insurance.

However, the unverified nature of these claims means the path to regulatory approval for anti-aging indications remains uncertain. Startups in this space should focus on validating these findings independently, as the market for longevity therapeutics is expanding but still lacks clear frameworks. The ARPA-H-funded study could be a bellwether for how regulators and payers respond to aging as a treatable condition.

This also underscores the importance of molecular biomarkers like aging clocks in drug development. Companies leveraging these tools may gain a competitive edge in demonstrating efficacy, attracting investment, and securing partnerships with incumbents like Eli Lilly and Novo Nordisk.

Key takeaways

• Eli Lilly and Novo Nordisk report that their GLP-1 drugs may reduce biological age by 2-3 years, with some measures showing up to 4 years of reduction.
• The findings are based on molecular 'aging clocks,' including proteomic and epigenetic clocks, which track biological markers of aging.
• These drugs are already associated with broader health benefits, such as improved kidney function and reduced blood pressure.
• A $38 million ARPA-H study aims to determine if semaglutide has anti-aging effects in healthy individuals over 60, potentially paving the way for new regulatory pathways.
• The results, while promising, are unverified and require further validation to confirm their implications for longevity and drug development.

FAQ

What are GLP-1 drugs, and how are they related to aging?

GLP-1 drugs, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are medications originally developed to treat type 2 diabetes and obesity. Recent research suggests they may also slow biological aging by reducing molecular markers of age, potentially acting as geroprotectors.

What are aging clocks?

Aging clocks are computational models that estimate biological age by analyzing molecular markers, such as proteins or epigenetic modifications. They provide insights into how quickly or slowly a person’s body is aging at a biological level.

How much did the drugs reduce biological age?

According to the reported findings, GLP-1 drugs reduced biological age by approximately 2 to 3 years, with some measures indicating up to 4 years of reduction.

Are these findings verified?

No, the findings are currently unverified. The research has not been independently confirmed or peer-reviewed, and further validation is needed.

What is the ARPA-H study?

ARPA-H, a U.S. government agency, has funded a $38 million study to explore semaglutide’s anti-aging effects in healthy individuals over 60. The study aims to define a regulatory pathway for anti-aging drugs and advance the field of longevity therapeutics.

Related on Lazyfounder

• More health news
• New Study: Transplanted Organs Adopt Recipient’s Biological Age